(Q35001038)

5 August 2017

1 reference

title

Development of thrombolytic therapy for stroke: a perspective (English)

1 reference

5 August 2017

1 reference

Paul A Lapchak

1

1 reference

5 August 2017

language of work or name

English

0 references

publication date

1 November 2002

1 reference

Expert Opinion on Investigational Drugs

5 August 2017

published in

1 reference

5 August 2017

volume

11

1 reference

5 August 2017

issue

11

1 reference

5 August 2017

page(s)

1623-1632

1 reference

Hemorrhagic transformation following ischemic stroke: significance, causes, and relationship to therapy and treatment

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.11.1623

Reducing bleeding complications after thrombolytic therapy for stroke: clinical potential of metalloproteinase inhibitors and spin trap agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.11.1623

Treatment of acute ischemic stroke.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.11.1623

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.11.1623

Thrombolytic therapy for ischemic stroke--a review. Part I--Intravenous thrombolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.11.1623

Tissue plasminogen activator for acute ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.11.1623

Systematic review of evidence on thrombolytic therapy for acute ischaemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.11.1623

Molecular mechanisms of plasminogen activation: bacterial cofactors provide clues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.11.1623

Immunohistochemistry of matrix metalloproteinases in reperfusion injury to rat brain: activation of MMP-9 linked to stromelysin-1 and microglia in cell cultures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.11.1623

Tissue plasminogen activator reduces neurological damage after cerebral embolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.11.1623

Alteplase for stroke: money and optimistic claims buttress the "brain attack" campaign

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.11.1623

Dichotomized efficacy end points and global end-point analysis applied to the ECASS intention-to-treat data set: post hoc analysis of ECASS I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.11.1623

Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.11.1623

Evaluation of early computed tomographic findings in acute ischemic stroke.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.11.1623

Thrombolysis for acute ischaemic stroke: consumer involvement in design of new randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.11.1623

Optimal timing of thrombolytic therapy in acute ischaemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.11.1623

Thrombolytic therapy within 3 to 6 hours after onset of ischemic stroke: useful or harmful?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.11.1623

Thrombolysis for acute ischemic stroke: still a treatment for the few by the few.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.11.1623

Pharmacological effects of the spin trap agents N-t-butyl-phenylnitrone (PBN) and 2,2,6, 6-tetramethylpiperidine-N-oxyl (TEMPO) in a rabbit thromboembolic stroke model: combination studies with the thrombolytic tissue plasminogen activator

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.11.1623

The nonpeptide glycoprotein IIb/IIIa platelet receptor antagonist SM-20302 reduces tissue plasminogen activator-induced intracerebral hemorrhage after thromboembolic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.11.1623

Safety of the weight-adjusted dosing regimen of tenecteplase in the ASSENT-Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.11.1623

Postischemic intracarotid treatment with TNK-tPA reduces infarct volume and improves neurological deficits in embolic stroke in the unanesthetized rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.11.1623

Neuroprotective effects of the spin trap agent disodium-[(tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (generic NXY-059) in a rabbit small clot embolic stroke model: combination studies with the thrombolytic tissue plasminogen activator

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.11.1623

Comparison of TNK with wild-type tissue plasminogen activator in a rabbit embolic stroke model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.11.1623

Thrombolytic therapy with streptokinase in acute ischemic stroke.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.11.1623

Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.11.1623

Local intra-arterial thrombolysis in acute ischemic stroke.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.11.1623

Cerebral hemorrhage after intra-arterial thrombolysis for ischemic stroke: the PROACT II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.11.1623

New plasminogen activators: a clinical review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.11.1623

Depletion of circulating alpha(2)-antiplasmin by intravenous plasmin or immunoneutralization reduces focal cerebral ischemic injury in the absence of arterial recanalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.11.1623

Role of plasminogen system components in focal cerebral ischemic infarction: a gene targeting and gene transfer study in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.11.1623

10.1517/13543784.11.11.1623

21 January 2018

Identifiers

DOI

1 reference

5 August 2017

1 reference